Open Journal of Endocrine and Metabolic Diseases
Vol.6 No.1(2016), Paper ID 63117, 8
pages
DOI:10.4236/ojemd.2016.61012
The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
Bruna de Souza Faustino, Alberto dos Reis Costa Junior, Letícia Nascimento Medeiros Bortolon, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Division of Endocrinology, IPEMED Medical School, Rio de Janeiro, Brazil
Visiting Scientist of the Harvard School of Public Health, Harvard University, Boston, USA
Copyright © 2016 Bruna de Souza Faustino, Alberto dos Reis Costa Junior, Letícia Nascimento Medeiros Bortolon, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Faustino, B. , Junior, A. , Bortolon, L. , de Sá, L. , Rocha, D. and Arbex, A. (2016) The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes.
Open Journal of Endocrine and Metabolic Diseases,
6, 87-94. doi:
10.4236/ojemd.2016.61012.